Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 5.34
+0.09 (1.71%)
Aug 27, 2026, 1:56 PM HKT
HKG:2566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,298 | 1,306 | 1,369 | 1,287 | 1,125 | 1,307 | |
Revenue Growth | -0.55% | -4.59% | 6.35% | 14.39% | -13.91% | - |
Cost of Revenue | 257.7 | 252.24 | 287.51 | 296.74 | 271.14 | 356.84 |
Gross Profit | 1,041 | 1,054 | 1,082 | 990.67 | 854.26 | 950.41 |
Selling, General & Admin | 749.93 | 785.77 | 808.38 | 723.62 | 649.02 | 686.08 |
Research & Development | 143.33 | 123.66 | 108.9 | 127.76 | 158.31 | 132.63 |
Other Operating Expenses | -4.17 | 3.33 | 7.36 | 1.87 | 1.02 | 1.42 |
Operating Expenses | 889.09 | 912.76 | 924.63 | 853.25 | 808.35 | 820.13 |
Operating Income | 151.69 | 141.3 | 157.05 | 137.42 | 45.91 | 130.28 |
Interest Expense | -5.81 | -5.66 | -7.15 | -9.39 | -9.04 | -9.72 |
Interest & Investment Income | 10.52 | 10.52 | 1.28 | 0.28 | 0.18 | 0.32 |
Currency Exchange Gain (Loss) | 0.22 | 0.22 | 1.08 | 0.21 | 0.2 | -0.12 |
Other Non Operating Income (Expenses) | 4.73 | 15.14 | 16.36 | 6.41 | 14.16 | 6.77 |
Pretax Income | 161.35 | 161.52 | 168.63 | 134.93 | 51.42 | 127.54 |
Income Tax Expense | 21.85 | 23.12 | 30.03 | 15.16 | -8.45 | 8.12 |
Net Income | 139.5 | 138.41 | 138.6 | 119.78 | 59.87 | 119.41 |
Net Income to Common | 139.5 | 138.41 | 138.6 | 119.78 | 59.87 | 119.41 |
Net Income Growth | 13.02% | -0.14% | 15.72% | 100.07% | -49.87% | - |
Shares Outstanding (Basic) | 244 | 245 | 204 | 200 | 200 | 200 |
Shares Outstanding (Diluted) | 244 | 245 | 204 | 200 | 200 | 200 |
Shares Change | 7.43% | 20.16% | 2.11% | - | - | - |
EPS (Basic) | 0.57 | 0.56 | 0.68 | 0.60 | 0.30 | 0.60 |
EPS (Diluted) | 0.57 | 0.56 | 0.68 | 0.60 | 0.30 | 0.60 |
EPS Growth | 5.21% | -16.89% | 13.32% | 100.07% | -49.87% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 205.25 | 79.69 | 114.66 | -0.74 | 13.59 |
Free Cash Flow Per Share | - | 0.84 | 0.39 | 0.57 | -0.00 | 0.07 |
Dividend Per Share | - | 0.057 | 0.056 | - | - | - |
Dividend Growth | - | 1.79% | - | - | - | - |
Gross Margin | 80.15% | 80.69% | 79.00% | 76.95% | 75.91% | 72.70% |
Operating Margin | 11.68% | 10.82% | 11.47% | 10.67% | 4.08% | 9.97% |
Profit Margin | 10.74% | 10.60% | 10.12% | 9.30% | 5.32% | 9.13% |
Free Cash Flow Margin | - | 15.71% | 5.82% | 8.91% | -0.07% | 1.04% |
EBITDA | 185.34 | 178.24 | 192.44 | 172.35 | 81.18 | 154.06 |
EBITDA Margin | 14.27% | 13.64% | 14.06% | 13.39% | 7.21% | 11.79% |
D&A For EBITDA | 33.65 | 36.94 | 35.39 | 34.93 | 35.27 | 23.78 |
EBIT | 151.69 | 141.3 | 157.05 | 137.42 | 45.91 | 130.28 |
EBIT Margin | 11.68% | 10.82% | 11.47% | 10.67% | 4.08% | 9.97% |
Effective Tax Rate | 13.54% | 14.31% | 17.81% | 11.23% | - | 6.37% |